Message #17 From:
Stock News Bot Date: November 8, 2006 06:30:00 AM
GTHA News GeneThera to Advance RNA Interference Work Through Collaboration Agreement
WHEAT RIDGE, Colo.--(BUSINESS WIRE)--GeneThera, Inc. (OTCBB:GTHA) is pleased to update its shareholders with
this release announcing the continuation of work done earlier by the
Company on RNA Interference (RNAi) in its Colorado laboratory.
RNA interference is used to regulate gene expression in the cells of
humans. Hundreds of genes in our genome encode small RNA molecules
called microRNAs. They contain pieces of the code of other genes. Such a
microRNA molecule can form a double-stranded structure and activate the
RNA interference machinery to block protein synthesis. The expression of
that particular gene is silenced. Genetic regulation by microRNAs plays
an important role in the development of the organism and the control of
cellular functions.
RNAi has already become an important research tool in biology and
biomedicine. In the future, it is hoped that it will be used in many
disciplines including clinical medicine and agriculture. Several recent
publications show successful gene silencing in human cells and
experimental animals. For instance, a gene causing high blood
cholesterol levels was recently shown to be silenced by treating animals
with silencing RNA. Plans are underway to develop silencing RNA as a
treatment for virus infections, cardiovascular diseases, cancer,
endocrine disorders and several other conditions.
“With the collaboration agreement in place
with IZSLER, GeneThera can now advance our previous research work to the
next stage with our access to experimentally infected cattle,”
said Dr. Tony Milici, CEO of GeneThera. “We
had received some promising results on some specific cell lines using
RNAi but were unable to continue the research until infected cattle were
available”.
“With a Nobel prize being issued this year to
two highly respected scientists for their discovery and research on
RNAi, we feel that it is of great importance for the regulation of gene
expression and it may lead to advances in vaccine programs for both
animals and humans. Large pharmaceutical companies are beginning to
understand the importance of RNAi as evidenced by Merck’s
recent purchase of Sirna Therapeutics and GeneThera hopes to further its
use of RNAi as a discovery tool in our TSE studies as well.”
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Wheat
Ridge, CO. The Company provides genetic diagnostic solutions for the
veterinary and agricultural industries with future plans to include the
health-care industry. The Company's proprietary diagnostic solution is
based on a genetic expression assay, GEA™, a
protocol designed to function on a highly automated Fluorogenic PCR
platform. This platform enables GeneThera to offer tests that are
presently not available from other technologies. The GEA™
is designed for a host of individual diseases, the current priority
being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk
and deer in North America; E.Coli 0157:H7 and Johnne's Disease, which
are diseases affecting cattle worldwide.
Stay up to date with Market NewsWire at www.mn1.com.
“Safe Harbor”
Statement:Certain statements in this release are “forward-looking”
statements as defined in the Private Securities Litigation Reform Act of
1995.Such statements are subject to numerous risks and
uncertainties.Actual results may vary significantly from the
results expressed or implied in such statements.Factors that
could cause actual results to materially differ from forward-looking
statements include, but are not limited to, the Company’s
ability to meet the terms and conditions required to obtain its project
financing, risks and delays associated with product development, risk of
market acceptance of new products, risk of technology or product
obsolescence, competitive risks, reliance on development partners and
the need for additional capital.
